BCDA - BioCardia, Inc.

2.01
0.025   1.244%

Share volume: 20,629
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$1.98
0.02
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 0%
Dept financing 26%
Liquidity 36%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-20.87%
3 Months
-5.47%
6 Months
-25.00%
1 Year
411.71%
2 Year
-93.30%
Key data
Stock price
$2.01
P/E Ratio 
0.00
DAY RANGE
$1.94 - $2.01
EPS 
-$2.42
52 WEEK RANGE
$0.30 - $5.69
52 WEEK CHANGE
$402.50
MARKET CAP 
9.994 M
YIELD 
N/A
SHARES OUTSTANDING 
2.124 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
3.53
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$202,693
AVERAGE 30 VOLUME 
$90,925
Company detail
CEO: Peter Alan Altman, PhD
Region: US
Website: biocardia.com
Employees: 40
IPO year: 2008
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

BioCardia, Inc. develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy.

Recent news
loading